Psychometric evaluation of the Taiwanese version of the functional assessment of cancer therapy: a questionnaire for patients with lung cancer

2018 ◽  
Vol 31 (7) ◽  
pp. 513-518
Author(s):  
Wen-Pei Chang ◽  
Yen-Kuang Lin ◽  
Chia-Chin Lin
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Cancer Therapy ◽  
Functional Assessment ◽  
Longitudinal Research ◽  
Characteristic Curve ◽  
Reliability And Validity ◽  
Psychometric Evaluation ◽  
Diagnosis Of Lung Cancer

Abstract Objective The Functional Assessment of Cancer Therapy-Lung (FACT-L) consists of the Functional Assessment of Cancer Therapy-General (FACT-G) and the Lung Cancer Subscale. The FACT-L is commonly used to measure quality of life in patients with lung cancer. This study evaluated the reliability and validity of the FACT-L in examining patients with lung cancer in Taiwan. Design This was a methodology study. Setting Patients with lung cancer at a regional hospital in Northern Taiwan. Participants Patients who had received an early diagnosis of lung cancer between 2013 and 2015 were recruited as respondents. Intervention(s) None. Main outcome measure(s) To verify the reliability and validity of the Taiwanese version of the FACT-L. Results A total of 104 patients who had received an initial diagnosis of lung cancer were recruited. The overall internal consistency of the FACT-L, as assessed using Cronbach’s α, was 0.82. Among the patients, 64 had a test–retest reliability (r) of 0.45 (P < 0.001) at 6 weeks after treatment. Moreover, longitudinal research indicated that the FACT-L detected score differences before and after treatment in these patients (Cohen’s d = −0.26). The Taiwanese version of the FACT-L considers 2-year survival as the gold standard, and the optimal combination of sensitivity and specificity was obtained when the receiver operating characteristic curve revealed cutoff points of 80 and 68 for the FACT-L and FACT-G, respectively. Conclusions The Taiwanese version of the FACT-L can be widely applied to assess the quality of life of patients with lung cancer.

Improvement in symptoms and quality of life (QoL) for patients (p) with non-small cell lung cancer (NSCLC) treated with erloninib: TargeT study

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 18140-18140
Author(s):  
V. Alberola ◽  
O. Gallego ◽  
G. López-Vivanco ◽  
C. Mesía ◽  
J. Oramas ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Cancer Therapy ◽  
Functional Assessment ◽  
Objective Response ◽  
Well Being ◽  
End Point ◽  
Trial Outcome Index ◽  
Outcome Index

18140 Background: Erlotinib is an EGFR TKI that is effective in the treatment of advanced NSCLC, in terms of longer survival, better quality of life and delayed symptom progression.We present here the outcome of a group of p from the TargeT study, whose QoL was assessed by the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire and the Lung Cancer Subscale (LCS). Methods: TargeT study was a multicenter, single-arm phase II study evaluating efficacy, safety, and tolerability of erlotinib (150 m/day) in p with stage IIIB or IV NSCLC, in 1st, 2nd and 3rd line treatment. Primary end-point was time to progression. QoL was a secondary end point as assessed monthly by the Functional Assessment of Cancer Therapy-Lung questionnaire (FACT- L) and its Lung Cancer Subscale. Physical and functional aspects of the QoL were measured by the Trial Outcome Index (TOI), which is the sum of the physical well being, functional well-being and LCS scores from the FACT-L questionnaire. Results: Data from 91 pts were available. QoL analysis showed that 53% of the p (95% IC 37–58%) had improvement in FACT-L or TOI. Similarly, 45% (95% IC35–56%) of improved their symptoms from baseline. Improvement was observed for each individual LCS item and specifically in the pulmonary items. In symptomatic p, shortened of breath was 17,6% at baseline vs 2.2% after treatment (p<0.001) and cough was 24.7% vs 8.8 % (p<0.001) after treatment. Those improvements in symptoms were rapid and, 73% of the patients who improved showed that recovery in the first cycle of treatment. In terms of association between efficacy of erlotinib and QoL, there is a statistically significative relationship between objective response and improvement in TOI or FACT-L (p<0.02). Conclusions: This QoL analysis confirms that erlotinib improves both symptoms and functional aspect of patients with NSCLC. The improvement in QoL is related with objective response. No significant financial relationships to disclose.

Quality of Life in Lung Cancer: The Validity and Cross-Cultural Applicability of the Functional Assessment of Cancer Therapy–Lung Scale

2005 ◽  
Vol 19 (2) ◽  
pp. 389-420 ◽  
Author(s):  
Zeeshan Butt ◽  
Kimberly Webster ◽  
Amy R. Eisenstein ◽  
Jennifer Beaumont ◽  
David Eton ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Cancer Therapy ◽  
Functional Assessment ◽  
Cross Cultural

Reliability and validity of the functional assessment of cancer therapy—lung (FACT-L) quality of life instrument

Lung Cancer ◽  
1995 ◽  
Vol 12 (3) ◽  
pp. 199-220 ◽  
Author(s):  
David F. Cella ◽  
Amy E. Bonomi ◽  
Stephen R. Lloyd ◽  
David S. Tulsky ◽  
Edward Kaplan ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cancer Therapy ◽  
Functional Assessment ◽  
Reliability And Validity ◽  
Life Instrument

scholarly journals Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy

2021 ◽  
Vol 18 (11) ◽  
pp. 5677
Author(s):  
Hsing-Wei Hung ◽  
Chien-Ying Liu ◽  
Hsiu-Fang Chen ◽  
Chun-Chu Chang ◽  
Shu-Ching Chen
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Peripheral Neuropathy ◽  
Cancer Therapy ◽  
Functional Assessment ◽  
Motor Impairment ◽  
Depression Scale ◽  
Advanced Lung Cancer ◽  
Platinum Based Chemotherapy

Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect of neurotoxic anticancer drugs that may affect quality of life (QoL). Purpose: The purposes of this study were to: assess the levels of CIPN, anxiety, depression, CIPN–related QoL, and general QoL; and identify the factors related to CIPN–related QoL and general QoL in patients with advanced lung cancer (LC) receiving platinum-based chemotherapy. This cross-sectional study examined patients with advanced LC who received platinum-based chemotherapy from the thoracic oncology inpatient wards of a medical center in northern Taiwan. Structured questionnaires were used to measure patients’ CIPN (European Organization for Research and Treatment of Cancer quality of life questionnaire–chemotherapy–induced peripheral neuropathy 20), anxiety (Hospital Anxiety and Depression Scale Depression Scale [HADS]), depression (HADS), CIPN-related QoL (Functional Assessment of Cancer Therapy /Gynecologic Oncology Group-Neurotoxicity subscale [FACT/GOG–Ntx]), and general QoL (Functional Assessment of Cancer Therapy–General Input [FACT-G]). Of 93 patients with advanced LC, 53.8% reported CIPN–sensory impairment and 47.3% reported CIPN–motor impairment. The most common CIPN symptoms were difficulty getting or maintaining an erection (only for men > 65 years) and difficulty in climbing stairs or getting up out of a chair. Poor CIPN–related QoL (FACT/GOG–Ntx) was associated with more CIPN–sensory and more CIPN–motor impairment. Poor general QoL (FACT-G) was associated with a higher level of depression, a higher level of anxiety, and receipt of more chemotherapy cycles. More than half of LC patients report impairment related to CIPN, calling for holistic treatment to improve QoL.

Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy

2003 ◽  
Vol 13 (6) ◽  
pp. 741-748 ◽  
Author(s):  
E. A. Calhoun ◽  
E. E. Welshman ◽  
C.-H. Chang ◽  
J. R. Lurain ◽  
D. A. Fishman ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Ovarian Cancer ◽  
Cancer Therapy ◽  
Functional Assessment ◽  
Gynecologic Oncology ◽  
Psychometric Evaluation ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
The Impact

The purpose of this study was to validate the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity (FACT/GOG-Ntx) questionnaire. The FACT/GOG-Ntx is the FACT-G plus an eleven-item subscale (Ntx subscale) that evaluates symptoms and concerns associated specifically with chemotherapy-induced neuropathy. Two groups of women with ovarian cancer completed the FACT/GOG-Ntx: one group with known neurotoxicities and one group of chemotherapy-naive women newly diagnosed with ovarian cancer. Levels of patient neuropathy, severity of toxicity, and patient quality of life from diagnosis of ovarian cancer to 12 months post-diagnosis were assessed. The Ntx subscale significantly differentiated the two groups at baseline and 3- and 6-month follow-ups, demonstrating significantly fewer problems among chemotherapy-naive patients than among patients with known neuropathy. The FACT/GOG-Ntx is a reliable and valid instrument for assessing the impact of neuropathy on health-related quality of life. The Ntx subscale demonstrated sensitivity to meaningful clinical distinctions and change over time.

Reliability and validity of the Functional Assessment of Cancer Therapy-melanoma (FACT-M)

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 8554-8554
Author(s):  
J. N. Cormier ◽  
K. Webster ◽  
D. Cella ◽  
M. I. Ross ◽  
J. E. Gershenwald ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cancer Therapy ◽  
Functional Assessment ◽  
Performance Status ◽  
Reliability And Validity ◽  
Retest Reliability ◽  
Melanoma Patients ◽  
Test Retest Reliability ◽  
Disease Specific

8554 Background: Our group has developed a disease-specific module for the Functional Assessment of Cancer Therapy (FACT) instrument to assess quality of life (QOL) in melanoma patients. The purpose of this study was to assess the reliability and validity of the melanoma subscale (MS) and melanoma surgery subscales (MSS) as well as the total FACT-M, which includes the FACT combined with the MS and MSS. Methods: 273 melanoma patients (stages I-IV) attending an outpatient melanoma clinic completed a battery of questionnaires at baseline assessment. The scores from the MS, MSS, and total FACT-M were compared to patient performance status (ECOG and Karnofsky scales), disease stage, treatment status, and other instruments with related domains including the Profile of Mood States, Marlowe-Crowne Social Desirability Scale, and the EORTC Quality of Life Questionnaire - melanoma module. Patients were assessed 1 week after baseline to assess test-retest reliability, and 163 patients completed assessments at 3 months to evaluate the responsiveness to change in performance status. Results: Internal consistency and test-retest reliability for the MS (Cronbach's a = 0.85, r = 0.81), MSS (a = 0.85, r = 0.82), and the total FACT-M (a = 0.95, r = 0.90) were excellent. Overall, the scales correlated with other measures and correlations were in the hypothesized direction. As predicted, FACT-M, MS, and MSS scores were lower for patients with advanced (stage III/IV) melanoma, patients with poor performance status, and patients who were receiving active treatment. In addition, total FACT-M, MS, and MSS scores were highly sensitive to changes in performance status (p = 0.0012, 0.0004, and 0.0006, respectively). Conclusions: The FACT-M is a reliable and valid QOL assessment tool for patients with melanoma. This disease-specific instrument should be utilized for melanoma QOL assessment in clinical trials. No significant financial relationships to disclose.

Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrument

Urology ◽  
1997 ◽  
Vol 50 (6) ◽  
pp. 920-928 ◽  
Author(s):  
Peg Esper ◽  
Fei Mo ◽  
Gerald Chodak ◽  
Michael Sinner ◽  
David Cella ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Cancer Therapy ◽  
Functional Assessment
Sign in / Sign up

Export Citation Format

Share Document